VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as its new chief financial officer, effective immediately. With over three decades of international financial leadership experience across global capital markets, investment banking, corporate finance, asset management, and strategic leadership, Willener is poised to play a pivotal role in the company's next phase of growth.
Willener will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company's capital strategy, identify strategic opportunities, and contribute to the continued development of its proprietary BiTAC(R) technology platform and oncology pipeline. His arrival comes at a critical time as VERAXA advances its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody-based formats toward clinical development.
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management. This extensive background in managing large-scale financial operations and strategic transactions is expected to be invaluable as VERAXA seeks to fund its research and development efforts and potentially pursue partnerships or other growth opportunities.
The appointment reflects VERAXA's commitment to strengthening its leadership team with seasoned professionals who can navigate the complexities of the biotech industry. The company's BiTAC technology, which stands for bispecific T cell engager, is designed to harness the power of the immune system to target and destroy cancer cells. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
Raju Willener's expertise in capital markets and corporate finance will be crucial for VERAXA as it aims to secure the necessary funding to advance its pipeline and potentially bring novel therapies to patients. The company's focus on next-generation antibody-based therapeutics positions it in a competitive and rapidly evolving field, where strategic financial leadership can make a significant difference in achieving milestones.
For more information about VERAXA and its latest updates, visit the company's newsroom at http://nnw.fm/VRXA. The full press release can be viewed at https://nnw.fm/jcHOU.
